NCT07739329Not yet recruitingPhase 4
A Study on the Preventive Effect of Electroacupuncture Combined With Dexmedetomidine in Post-stroke Depression
Source: ClinicalTrials.gov · Last updated 31 Jul 2026
Brief summary (registry, in English)
Post-stroke depression (PSD) is a common neuropsychiatric complication following stroke and has emerged as a major public health concern due to its adverse impact on post-stroke prognosis. Clinical studies have confirmed that early intervention with electroacupuncture can significantly reduce PSD incidence and alleviate depressive severity. Mechanistically, electroacupuncture exerts antidepressant effects through inhibition of the endoplasmic reticulum stress pathway and attenuation of neuronal apoptosis. Dexmedetomidine, a highly selective α₂-adrenergic receptor agonist, not only provides sedation and analgesia but also confers neuroprotective actions, including anti-inflammatory, anti-apoptotic, and blood-brain barrier protective effects. Its efficacy in preventing postpartum depression has been clinically validated. Given the substantial burden of PSD and the limitations of existing preventive approaches, the present study aims to investigate the value of a combined electroacupuncture and dexmedetomidine strategy for PSD prevention, with the goal of developing a safe and effective integrative treatment regimen for this frequent post-stroke complication.
- Status (registry)
- Not yet recruiting
- Phase (registry)
- Phase 4
- Study type
- Interventional
- Enrollment
- 231 (estimated)
- First submitted
- 28 Jul 2026
- Start date
- 1 Aug 2026
- Primary completion date
- 31 Dec 2026
- Lead sponsor
- Min Su
- Diseases
- Stroke
- NCT number
- NCT07739329
What you commit to
- Study type: Interventional · Phase 4
- Planned participants: 231
- From 1 Aug 2026 to the primary completion date, 31 Dec 2026
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Use of sedatives or antipsychotic medications within 2 weeks prior to screening;
Other illness
- Cognitive impairment;
- Severe aphasia or significant language impairment;
- History of psychiatric disorders, including but not limited to depression, schizophrenia, and bipolar disorder;
- Severe cardiac, hepatic, or renal dysfunction;
- Complicated with acute severe conditions or unstable vital signs;
- Known allergy to any of the study medications;
Lab values
- Sick sinus syndrome, severe bradycardia (heart rate \< 50 bpm), second-degree or higher atrioventricular block, permanent pacemaker implantation, severe heart failure, or ejection fraction \< 30%;
Other
- Disturbance of consciousness;
- Alcohol or substance dependence;
- Pregnancy or lactation;
- Contraindications or intolerance to electroacupuncture;
- Inability to complete the study procedures due to any unavoidable circumstances.
Who the study is looking for
- Ischemic stroke with a disease course of less than 2 weeks;
- Patients with high-risk PSD;
- The patient can accept the treatment plan described in this trial and sign the informed consent form.
Sex: All · Does not accept healthy volunteers
This page is information, not medical advice. Discuss any trial with your doctor.